Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors
Antonia F. Stepan(Pfizer (United States)), R. Scott Obach(Pfizer (United States)), Annie Won(Pfizer (United States)), Jason K. Dutra(Pfizer (United States)), E. Sibley(Pfizer (United States)), David Riddell(Eli Lilly (United States)), Theresa J. O’Sullivan(Pfizer (United States)), Emily Miller(Pfizer (United States)), Peter H. Dorff(Pfizer (United States)), Christopher J. O’Donnell(Pfizer (United States)), W. Scott McDonald(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Leslie R. Pustilnik(Pfizer (United States)), Chakrapani Subramanyam(Pfizer (United States)), Blossom Sneed(Pfizer (United States)), Kenneth J. DiRico(Pfizer (United States)), S.H. Capetta(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), Anthony Wood(Pfizer (United Kingdom)), Hao Sun(Chinese Academy of Sciences), Stacey L. Becker(Pfizer (United States)), Ivan Efremov(Pfizer (United States)), Kapil Karki(Pfizer (United States)), Yasong Lu(Pfizer (United States)), A.J. Hallgren(Pfizer (United States))
Cited by 106
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302